The demand for CDMO (Contract Development and Manufacturing Organization) services in the pharmaceutical and biotechnology industries is rising sharply. As innovative treatments for complex diseases increase, companies are partnering with CDMOs to speed up development and commercialization. Additionally, artificial intelligence (AI) is transforming workflows, improving efficiency, and supporting global market growth.
In 2024, North America dominated the global CDMO services market, holding a 44.1% share. This leadership is driven by strong healthcare infrastructure, ongoing R&D investments, and a high rate of outsourcing by pharma and biotech companies.
Looking forward, Asia Pacific is set to be the fastest-growing region from 2025 to 2030. Countries like China and India are witnessing rising investments, clinical trials, and government support for CDMO services, positioning the region as a global manufacturing hub.
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/download-databook/5801
The API manufacturing segment emerged as the largest in 2024, holding a 41.3% market share. APIs (Active Pharmaceutical Ingredients) are vital for all medicines, and CDMOs help reduce production costs while ensuring compliance with regulations. This segment is also projected to register the fastest growth over the forecast period.
In 2024, small molecules dominated the market with a 58.2% share, supported by their widespread application in drug development. However, advanced therapies are anticipated to grow at the fastest pace in the coming years, driven by increasing demand for gene and cell therapies for chronic and rare diseases.
By phase, the commercial segment led the market in 2024 with a 64.7% share. CDMOs play a critical role in large-scale production, quality assurance, and regulatory compliance during this phase. Meanwhile, the clinical segment is expected to grow rapidly as pharma and biotech companies seek to streamline clinical trials and accelerate product approvals.
Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5801
Pharmaceutical companies were the primary end users of CDMO services in 2024, accounting for a 69.5% market share. Their continuous drug development pipelines drive outsourcing needs. Biotech companies, however, are expected to show the highest growth, fueled by increasing biologics and advanced therapies production.
The oncology segment was the largest therapeutic area in 2024, with a 33.8% share. Cancer treatments often require specialized CDMO support for production and clinical trials. The rare diseases segment is projected to grow fastest due to rising innovation in orphan drug development and supportive regulatory frameworks.
AI is revolutionizing CDMO operations by improving quality, reducing time-to-market, and cutting costs. It helps optimize production conditions, predict potential issues, and enhance drug development processes. Predictive analytics and machine learning are also enabling smarter decision-making and operational efficiency.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
June 2025: TAG1 Inc. partnered with PharmaLogic to improve accessibility to Pb-212 generators for radiopharmaceuticals.
June 2025: OneSource Specialty Pharma Limited collaborated with Xbrane Biopharma AB for biosimilar manufacturing.
June 2025: LOTTE BIOLOGICS signed a deal with Ottimo Pharma to support antibody therapeutics development.
April 2025: PCI Pharma Services acquired Ajinomoto Althea to expand sterile fill-finish capabilities in North America.
March 2025: Shilpa Medicare launched a hybrid CDMO to offer flexible pathways for pharma and biotech companies.
These collaborations highlight the growing reliance on CDMO services to support complex drug development and manufacturing needs globally.
The growth is driven by increased outsourcing from pharma and biotech companies, the rise of innovative therapies, and the integration of AI for improved efficiency and cost savings.
API manufacturing dominates because of its critical role in drug production and the cost efficiencies CDMOs provide for API development and scaling.
AI enhances quality control, reduces downtime, optimizes production conditions, and speeds up drug development, making CDMO operations more efficient and cost-effective.
Asia Pacific is projected to grow the fastest from 2025 to 2030, supported by rising investments, government initiatives, and the expanding pharma and biotech industries.
Biotech companies are leveraging CDMO expertise to develop biologics, gene therapies, and other advanced treatments that require specialized facilities and regulatory compliance.
To access the full market report : https://www.towardshealthcare.com/price/5801
The direct-to-consumer genetic testing market is projected to grow from USD 2.45 billion in 2024 to USD 21.85 billion by… Read More
The global healthcare contact center as a service market was valued at USD 5.86 billion in 2024, grew to USD… Read More
The global medical membrane market was valued at USD 4.26 billion in 2024 and is expected to grow to USD… Read More
The global surgical sutures market, also known as the medical stitches industry, is on a steady growth trajectory. Surgical sutures… Read More
The global medical imaging market was valued at USD 41.64 billion in 2024 and is projected to increase to USD… Read More
The global pharma contract research organization (CRO) services market is experiencing significant growth, projected to expand from USD 36.66 billion… Read More